LSB Stock Overview
A biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
LakeShore Biopharma Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.71 |
| 52 Week High | US$1.75 |
| 52 Week Low | US$0.35 |
| Beta | 0.62 |
| 1 Month Change | -26.88% |
| 3 Month Change | 13.49% |
| 1 Year Change | -50.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.23% |
Recent News & Updates
Shareholder Returns
| LSB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.5% | -1.8% | 1.6% |
| 1Y | -50.0% | 5.5% | 22.3% |
Return vs Industry: LSB underperformed the US Biotechs industry which returned 5.5% over the past year.
Return vs Market: LSB underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| LSB volatility | |
|---|---|
| LSB Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: LSB's share price has been volatile over the past 3 months.
Volatility Over Time: LSB's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 754 | Dave Chenn | www.ysbiopharm.com |
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines.
LakeShore Biopharma Co., Ltd Fundamentals Summary
| LSB fundamental statistics | |
|---|---|
| Market cap | US$129.97m |
| Earnings (TTM) | -US$45.98m |
| Revenue (TTM) | US$75.00m |
1.8x
P/S Ratio-2.9x
P/E RatioIs LSB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LSB income statement (TTM) | |
|---|---|
| Revenue | CN¥544.09m |
| Cost of Revenue | CN¥107.51m |
| Gross Profit | CN¥436.58m |
| Other Expenses | CN¥770.14m |
| Earnings | -CN¥333.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.77 |
| Gross Margin | 80.24% |
| Net Profit Margin | -61.31% |
| Debt/Equity Ratio | 115.7% |
How did LSB perform over the long term?
See historical performance and comparison